Roswell Park selects Circuit Clinical as collaborator for CIMAvax clinical trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Circuit Clinical announced a collaboration with Roswell Park Comprehensive Cancer Center to support the expansion of clinical trial opportunities to its outpatient oncology practices. This collaboration marks Circuit Clinical’s entry into oncology clinical research, with both digital and clinical services.

Circuit Clinical will be delivering both research operational support and TrialScout– its patient experience platform– in support of Roswell Park’s groundbreaking CIMAvax-EGF Clinical Trial.

Circuit Clinical will be providing patient identification, engagement, enrollment and ongoing patient experience support services under the direction of the Roswell Park Comprehensive Cancer Center clinical research leadership team.

In addition to its main campus on Carlton Street in the City of Buffalo, Roswell Park offers care at satellite offices in Amherst and Niagara Falls and at five affiliated community practices.

Through this collaboration, eligible patients with certain forms of lung and head/neck cancer will have the opportunity to participate in the CIMAvax Clinical Trial onsite at one or more of the following practices:

  • Roswell Park Jamestown Medical Oncology & Hematology,

  • Roswell Park Hematology Oncology of Niagara,

  • Roswell Park Hematology Oncology Southtowns,

  • Roswell Park Hematology Oncology Northtowns.

Table of Contents

YOU MAY BE INTERESTED IN

If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login